Buffett’s Berkshire cuts stakes in U.S. drugmakers, invests in drug royalty company -Breaking
(Reuters) – Warren Buffett’s Berkshire Hathaway (NYSE:) Inc said on Monday it eliminated its investment in Merck & Co and reduced its stakes in Abbvie Inc and Bristol-Myers Squibb (NYSE:) Co, as it pared its overall stock market investments.
These changes were made public in a regulatory filing that listed Berkshire’s U.S.-listed holdings at Sept. 30, 2018.
Berkshire also disclosed new investments in Royalty Pharma Plc, which buys pharmaceutical royalties, and flooring retailer Floor & Decor Holdings (NYSE:) Inc.
Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.